Home›Trial›NCT05624268
🔬NCT05624268Phase 3ACTIVE NOT RECRUITING

Efficacy, Safety, and Tolerability of COMP360 in Participants With TRD

Study Summary

Efficacy, Safety, and Tolerability of a single administration of COMP360 in participants with treatment-resistant depression (TRD)

Conditions
Treatment Resistant Depression
Interventions / Drugs
Psilocybin
View on ClinicalTrials.gov ↗
Sponsor
CMPS
COMPASS Pathways
Mental Health
D39/100
Study Details
Enrollment255 participants
Primary Completion—
Lead SponsorCOMPASS Pathways
Data Retrieved2026-04-11 04:09:48.956160+00:00
Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.